From a Particle Physics PhD at Imperial College ... world of a Fortune 25 company, working as a Data Lead in Analytics. Beyond her work in Analytics, Andri wears many hats: she’s a 3-Dan Martial Arts ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Their unparalleled opportunities for attaining a degree with worldwide recognition include being based in an incredibly ...

New observations have dramatically reduced the chances of asteroid 2024 YR4 hitting Earth in 2032, lowering the risk to ...

The Crespo scale is a scale that ranks the 'danger' of an animal species based on how much of a threat it presents towards a ...

London's town halls can help pull in the tech investment that will drive UK's growth - Local authorities can bring organisations and people together who can help deliver economic progress for all.

Google AI could rapidly accelerate the pace of scientific and medical discoveries - and researchers are already singing its ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

Until recently getting to Khaira from Kanharpuri, a bigger settlement, involved a roundabout route on potholed surfaces. But ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Scientists across Africa, America, Asia, Australia, and Europe outline for the first time how Artificial Intelligence (AI) can transform the landscape of infectious disease research and improve ...